DE602004026071D1 - Aminopyrone und ihre verwendung als atm inhibitoren - Google Patents

Aminopyrone und ihre verwendung als atm inhibitoren

Info

Publication number
DE602004026071D1
DE602004026071D1 DE602004026071T DE602004026071T DE602004026071D1 DE 602004026071 D1 DE602004026071 D1 DE 602004026071D1 DE 602004026071 T DE602004026071 T DE 602004026071T DE 602004026071 T DE602004026071 T DE 602004026071T DE 602004026071 D1 DE602004026071 D1 DE 602004026071D1
Authority
DE
Germany
Prior art keywords
group
optionally substituted
aminopyrone
atm inhibitors
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004026071T
Other languages
English (en)
Inventor
Graeme Cameron M Smith
Niall Morrison B Martin
Xiao-Ling Fan Cockcroft
Ian Timothy Williams Matthews
Keith Allan Menear
Laurent Jean Martin Rigoreau
Marc Geoffrey Hummersone
Roger John Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kudos Pharmaceuticals Ltd
Original Assignee
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kudos Pharmaceuticals Ltd filed Critical Kudos Pharmaceuticals Ltd
Publication of DE602004026071D1 publication Critical patent/DE602004026071D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004026071T 2003-08-13 2004-08-13 Aminopyrone und ihre verwendung als atm inhibitoren Active DE602004026071D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49477603P 2003-08-13 2003-08-13
PCT/GB2004/003507 WO2005016919A1 (en) 2003-08-13 2004-08-13 Aminopyrones and their use as atm inhibitors

Publications (1)

Publication Number Publication Date
DE602004026071D1 true DE602004026071D1 (de) 2010-04-29

Family

ID=34193236

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004026071T Active DE602004026071D1 (de) 2003-08-13 2004-08-13 Aminopyrone und ihre verwendung als atm inhibitoren

Country Status (19)

Country Link
US (2) US7429660B2 (de)
EP (1) EP1654257B1 (de)
JP (1) JP2007501836A (de)
KR (1) KR20060066722A (de)
CN (1) CN1867566B (de)
AT (1) ATE461193T1 (de)
AU (1) AU2004265149A1 (de)
BR (1) BRPI0413467A (de)
CA (1) CA2534300A1 (de)
DE (1) DE602004026071D1 (de)
ES (1) ES2341342T3 (de)
GB (1) GB2420781B (de)
HK (1) HK1097273A1 (de)
MX (1) MXPA06001599A (de)
NO (1) NO20061126L (de)
NZ (1) NZ545919A (de)
TW (1) TW200524924A (de)
WO (1) WO2005016919A1 (de)
ZA (1) ZA200601595B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
KR20060066722A (ko) * 2003-08-13 2006-06-16 쿠도스 파마슈티칼스 리미티드 아미노피론 및 atm억제제로서의 이의 용도
US20070238731A1 (en) 2004-09-20 2007-10-11 Kudos Pharmaceuticals Limited Dna-Pk Inhibitors
CN101115747A (zh) * 2005-02-09 2008-01-30 库多斯药物有限公司 Atm抑制剂
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
US20070049588A1 (en) * 2005-08-31 2007-03-01 Kudos Pharmaceuticals Limited Atm inhibitor
US8318688B2 (en) 2005-12-19 2012-11-27 Northwestern University Compositions and methods for altering RNAi
US20080279866A1 (en) * 2006-08-25 2008-11-13 The Brigham And Women's Hospital, Inc. Induction of immunosuppression by inhibition of ATM
EP2117575A4 (de) 2007-01-03 2013-06-05 Burnham Inst Medical Research Verfahren und zusammensetzungen in verbindung mit gerinnselbindenden verbindungen
WO2008080398A1 (en) * 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
JP2013515008A (ja) 2009-12-18 2013-05-02 サンフォード−バーナム メディカル リサーチ インスティテュート 凝血塊結合化合物に関連する方法および組成物
WO2013003112A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013043744A2 (en) 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
EP3042900B1 (de) * 2013-08-29 2020-09-23 Fujifilm Corporation Neuartige morpholinderivate oder salz davon
KR20160049435A (ko) 2014-10-27 2016-05-09 삼성전자주식회사 Atm 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
US11547703B2 (en) 2017-02-27 2023-01-10 Impact Therapeutics (Shanghai), Inc Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
US20200355997A1 (en) * 2019-05-08 2020-11-12 Facebook Technologies, Llc Thianthrene derivatized monomers and polymers for volume bragg gratings
US11718580B2 (en) 2019-05-08 2023-08-08 Meta Platforms Technologies, Llc Fluorene derivatized monomers and polymers for volume Bragg gratings
US11780819B2 (en) 2019-11-27 2023-10-10 Meta Platforms Technologies, Llc Aromatic substituted alkane-core monomers and polymers thereof for volume Bragg gratings
EP4171651A1 (de) 2020-06-24 2023-05-03 AstraZeneca UK Limited Kombination aus antikörper-wirkstoff-konjugat und atm-inhibitor
US11879024B1 (en) 2020-07-14 2024-01-23 Meta Platforms Technologies, Llc Soft mold formulations for surface relief grating fabrication with imprinting lithography

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (de) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
HUT58310A (en) 1988-12-21 1992-02-28 Upjohn Co Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
DE69127690T2 (de) 1990-06-20 1998-02-12 Pharmacia & Upjohn Company Kal Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
ATE128128T1 (de) 1990-06-29 1995-10-15 Upjohn Co Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
EP0610519B1 (de) 1992-09-02 1999-12-01 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv-medikament
JP3521145B2 (ja) * 1993-04-09 2004-04-19 富山化学工業株式会社 免疫調節剤,細胞接着阻害剤および自己免疫疾患の治療・予防剤
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1997018323A2 (en) 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
EP0990028A4 (de) 1997-06-06 2000-09-27 Mayo Foundation For Medical Screening auf inhibitoren der phosphatidylinositol verwandten kinase
WO1998056391A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
EP1257537B1 (de) 2000-01-24 2007-05-30 AstraZeneca AB Durch einen morpholinrest substituierte therapeutische verbindungen
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6894055B2 (en) 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
AU2003209990B8 (en) 2002-02-25 2008-10-30 Kudos Pharmaceuticals Ltd Pyranones useful as ATM inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
KR20060066722A (ko) * 2003-08-13 2006-06-16 쿠도스 파마슈티칼스 리미티드 아미노피론 및 atm억제제로서의 이의 용도
US20070238731A1 (en) * 2004-09-20 2007-10-11 Kudos Pharmaceuticals Limited Dna-Pk Inhibitors
CN101115747A (zh) 2005-02-09 2008-01-30 库多斯药物有限公司 Atm抑制剂
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
AU2004265149A1 (en) 2005-02-24
EP1654257B1 (de) 2010-03-17
GB2420781B (en) 2008-07-09
NZ545919A (en) 2009-07-31
ZA200601595B (en) 2007-03-28
BRPI0413467A (pt) 2006-10-17
US20050054657A1 (en) 2005-03-10
KR20060066722A (ko) 2006-06-16
JP2007501836A (ja) 2007-02-01
HK1097273A1 (en) 2007-06-22
MXPA06001599A (es) 2006-05-19
CN1867566A (zh) 2006-11-22
NO20061126L (no) 2006-05-09
WO2005016919A1 (en) 2005-02-24
US20090043091A1 (en) 2009-02-12
GB2420781A (en) 2006-06-07
ES2341342T3 (es) 2010-06-18
EP1654257A1 (de) 2006-05-10
GB0604321D0 (en) 2006-04-12
TW200524924A (en) 2005-08-01
US7429660B2 (en) 2008-09-30
CN1867566B (zh) 2010-06-16
CA2534300A1 (en) 2005-02-24
ATE461193T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
HK1097273A1 (en) Aminopyrones and their use as atm inhibitors
HK1069827A1 (en) Pyranones useful as atm inhibitors.
TW200616986A (en) DNA-pk inhibitors
DK1417196T3 (da) DNA-PK inhibitorer
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
TW200638938A (en) ATM inhibitors
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
GB0119863D0 (en) DNA-PK inhibitors
DE602006020458D1 (de) Carbonsäureamidverbindung und deren verwendung
CO5580804A2 (es) Derivados de diazepanes utiles como inhibidores de lfa
TH92038B (th) อนุพันธ์คาร์บอกซาไมด์ที่มีลักษณะเอไมด์
ATE407129T1 (de) Pentafluoroalkylsulfin-naphthaline und und darauf bezogene modulatoren des östrogenrezeptors
TH92038A (th) อนุพันธ์คาร์บอกซาไมด์ที่มีลักษณะเอไมด์

Legal Events

Date Code Title Description
8364 No opposition during term of opposition